Skip to main content
Log in

Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

We compared concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and 5-fluorouracil (5-FU) (TPF) with CCRT with CDDP, 5-FU, methotrexate and leucovorin (PFML) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) in terms of safety and efficacy on survival. A total of 100 patients were enrolled. The TPF group received CCRT with the TPF regimen [docetaxel (50 mg/m2: day 1), CDDP (60 mg/m2: day 4), and continuous 5-FU infusion (600 mg/m2/day: days 1–5)]. In the PFML group, patients received CCRT with the PFML regimen [CDDP (60 mg/m2: day 4)], continuous 5-FU infusion (600 mg/m2/day: days 1–5), methotrexate (30 mg/m2: day 1) and leucovorin (20 mg/m2/day: days 1–5)]. Both groups received 2 cycles of chemotherapy during definitive radiotherapy. The total radiation dose was between 66.6 and 70.2 Gray. The overall response rates after CCRT were 98 with 90% of a pathologically complete response (pCR) in the TPF group and 94 with 77% in the PFML group. For grade 3/4 adverse events, mucositis was more frequent in the PMFL group, and the TPF group showed a higher incidence of hematological toxicity. CCRT with TPF or PMFL for advanced SCCHN was tolerable and produced excellent survival rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31

    Article  CAS  PubMed  Google Scholar 

  2. Clayman GL, Lipman SM, Laramore GE, Ki Hong W (2000) Head and neck neoplasms. In: Holland JF, Kufe DW, Pollock RE et al (eds) Holland–Frei cancer medicine, 5th edn. BC Decker, Philadelphia, pp 1173–1220

    Google Scholar 

  3. Pignon JP, Bourhis J, Domenge C, Designé L, MACH-NC Collaborative Group (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949–955

    CAS  PubMed  Google Scholar 

  4. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E (2002) End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 13:995–1006

    Article  CAS  PubMed  Google Scholar 

  5. Bourhis J, Le Maître A, Baujat B, Audry H, Pignon JP, Meta-Analysis of Chemotherapy in Head, Neck Cancer Collaborative Group, Meta-Analysis of Radiotherapy in Carcinoma of Head, Neck Collaborative Group, Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma Collaborative Group (2007) Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol 19:188–194

    Article  PubMed  Google Scholar 

  6. Pignon JP, Syz N, Posner M, Olivares R, Le Lann L, Yver A, Dunant A, Lewin F, Dalley DN, Paccagnella A, Taylor SG, Domenge C, Bourhis J, Mazumdar M (2004) Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction chemotherapy may offer survical benefit in squamous cell cancer of the head and neck. Anticancer Drugs 15(4):331–340

    Article  CAS  PubMed  Google Scholar 

  7. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL, EORTC 24971/TAX 323 Study Group (2007) Cisplatin, fluorouracil, and decetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704

    Article  CAS  PubMed  Google Scholar 

  8. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI, TAX 324 Study Group (2007) Cisplatin and fluorouracil alone or with decetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715

    Article  CAS  PubMed  Google Scholar 

  9. Seiwert TY, Cohen EEW (2005) State of the art management of locally advanced head and neck cancer. Br J Cancer 92:1341–1348

    Article  CAS  PubMed  Google Scholar 

  10. Salama JK, Seiwert TY, Vokes EE (2007) Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 25(26):4118–4126

    Article  CAS  PubMed  Google Scholar 

  11. Tsukuda M, Mikami Y, Tanigaki Y, Katori H, Horiuchi C, Ikeda Y, Taguchi T, Ono M, Yoshida T, Sakuma Y, Aikoh K (2004) Phase 1 trial of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) for patients with locally locally advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol 9:161–166

    Article  CAS  PubMed  Google Scholar 

  12. Katori H, Tsukuda M, Mochimatu I, Ishitoya J, Kawai S, Mikami Y, Matsuda H, Tanigaki Y, Horiuchi C, Ikeda Y, Taguchi T, Ono M, Yoshida T, Hirose S, Sakuma Y, Yamamoto K (2004) Phase 1 trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90:348–352

    Article  CAS  PubMed  Google Scholar 

  13. Katori H, Tsukuda M, Watai K (2007) Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Cancer Chemother Pharmacol 60(3):399–406

    Article  CAS  PubMed  Google Scholar 

  14. Katori H, Tsukuda M (2005) Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Oncol (R Coll Radiol) 17(3):148–152

    CAS  Google Scholar 

  15. Taguchi T, Tsukuda M, Katori H (2006) Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx. Acta Otolaryngol 126:408–413

    Article  CAS  PubMed  Google Scholar 

  16. Katori H, Tsukuda M, Taguchi T (2007) Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 59(6):789–794

    Article  CAS  PubMed  Google Scholar 

  17. Taguchi T, Tsukuda M, Mikami Y, Matsuda H, Tanigaki Y, Horiuchi C, Nishimura G, Nagao JI (2009) Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Auris Nasus Larynx 36(2):199–204

    Article  PubMed  Google Scholar 

  18. World Health Organization (1979) WHO Handbook for reporting results of cancer treatment. WHO offset publication No. 48. World Health Organization, Geneva

    Google Scholar 

  19. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098

    Article  CAS  PubMed  Google Scholar 

  20. Cohen EE, Lingen MW, Vokes EE (2004) The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22:1743–1752

    Article  PubMed  Google Scholar 

  21. Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, Leblanc M, Ensley JF, Schuller DE (2005) Organ preservation for advanced respectable cancer of the base of tongue and hypopharynx: a southwest oncology group trial. J Clin Oncol 23(1):88–95

    Article  PubMed  Google Scholar 

  22. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P, Lorenz RR, Carroll MA (2006) Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer. J Clin Oncol 24(7):1064–1071

    Article  CAS  PubMed  Google Scholar 

  23. Bensadoun RJ, Bénézery K, Dassonville O, Magné N, Poissonnet G, Ramaïoli A, Lemanski C, Bourdin S, Tortochaux J, Peyrade F, Marcy PY, Chamorey E, Vallicioni J, Seng H, Alzieu C, Géry B, Chauvel P, Schneider M, Santini J, Demard F, Calais G (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 yaers (FNCLCC-GHORTEC). Int J Radiat Oncol Biol Physi 64(4):983–994

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mamoru Tsukuda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsukuda, M., Ishitoya, J., Matsuda, H. et al. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 66, 729–736 (2010). https://doi.org/10.1007/s00280-009-1217-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1217-0

Keywords

Navigation